DAIICHI-SANKYO
Daiichi Sankyo (TSE: 4568) today announced that it has opened a new affiliate for its oncology business in Athens, Greece. The establishment highlights the company’s strong commitment to addressing treatment needs of people living with cancer in the European region. Thomais Konstantopoulou has been appointed Country Manager, Daiichi Sankyo Greece Single Member S.A.
“We are very happy to open yet another new affiliate in Europe to bring our innovative medicines to patients who can benefit from them. To have representation in a country is the best way of doing this,” said Thomais Konstantopoulou, Country Manager, Daiichi Sankyo Greece. “Our decision to establish a presence in Greece stems from our deep-rooted commitment to serving as many patients with cancer as possible with our innovative portfolio, aiming to improve outcomes and quality of life. It also is linked to a continuous effort of multiple stakeholders that elevates oncology in the country’s healthcare agenda and promotes active dialogue. Daiichi Sankyo is investing in Greece, which aligns with the country’s ambition to create conditions that foster innovation, talent retention, technology advancement and economic growth. We are focused on advancing meaningful innovation and creating jobs in a sustainable manner.”
Daiichi Sankyo has affiliates in 14 European countries, alongside representations in Norway, Finland, Sweden and Luxembourg. Europe has always been a focus for the company’s medicines, as well as a key region for continuous investment. With 20 research and development sites across 12 countries, Daiichi Sankyo utilizes a global network to drive innovation. Currently, the company is focused on developing antibody drug conjugates (ADCs), which are targeted cancer medicines that combine target-specificity and anti-tumor activity in a single molecule.
“From pursuing new medicines and new methods of drug discovery and delivery to achieving excellence throughout our organization by continuously examining new ideas, innovation is paramount for all we do,” said Dr. Dimitrios Krikelis, Head of Medical Affairs, Daiichi Sankyo Greece. “Even before the establishment of the Greek affiliate, Daiichi Sankyo has been partnering with the local oncology community through our clinical development program. We are fortunate to have physicians with a wealth of clinical expertise and a vibrant research community in Greece.”
Daiichi Sankyo aims to be an active contributor to the Greek healthcare ecosystem by partnering with the scientific community, governmental organizations and patient advocacy groups in order to provide value to patients, healthcare professionals and health authorities.
About Daiichi Sankyo
Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information, please visit www.daiichi-sankyo.eu.
HQ/ONP/07/24/0007
| _______________________________ |
1 https://www.jto.org/article/S1556-0864(20)31099-6/fulltext |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709254444/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Neuraptive Therapeutics Announces Presentation of Phase 2 Topline Interim Results for NTX-001 at the 2024 American Society for Surgery of the Hand (ASSH) Annual Meeting19.9.2024 18:31:00 CEST | Press release
- Interim 24-week data from the NEUROFUSE study highlights the safety and efficacy of NTX-001 for peripheral nerve injuries. Neuraptive Therapeutics Inc., a leading biopharmaceutical company focused on novel treatments for peripheral nerve injuries, today announced that interim topline results from its ongoing Phase 2 NEUROFUSE Study will be presented at the 2024 American Society for Surgery of the Hand (ASSH) Annual Meeting, held September 19-21 in Minneapolis, MN. The presentation, titled Safety and Efficacy of NTX-001 in the Treatment of Acute Single Transected Peripheral Nerve Injuries: A Phase 2 Randomized Controlled Trial, was awarded a Top 10 Best Paper designation and will be presented by Dr. David Brogan of Washington University during the scientific paper session on Thursday, September 19. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240919597699/en/ David M. Brogan, MD, MSc, Assistant Professor, Orthopaedic Surg
Sandvine: Our Next Chapter as a Market Leader for Technology Solutions19.9.2024 18:26:00 CEST | Press release
With new owners, a commitment to new leadership, and reoriented business model, today we announce the next chapter of Sandvine as a technology solution leader for democracies. Our technology facilitates internet access for hundreds of millions of people around the globe. We work with the world’s largest internet service providers to classify network traffic, enhance network connectivity, and counter threats to network security. Our mission is to help people work, learn, entertain and communicate. In response to concerns regarding the misuse of our technology by foreign governments, we made a commitment to new ownership, leadership, and business strategy. In the last several months, we have committed to significant changes to our governance and business model in consultation with the U.S. Department of Commerce, the U.S. Department of State, and other key members of the U.S. government. These transformative changes include: Focusing Our Global Operations to Democracies in Support of Int
HarbourVest Partners Appoints Tjalling (TJ) Halbertsma as a Managing Director19.9.2024 18:15:00 CEST | Press release
HarbourVest Partners, the global private markets investment specialist, today announced the appointment of Tjalling (TJ) Halbertsma as managing director and Head of EMEA Investor Relations. “We are excited to welcome TJ to HarbourVest,” said John Toomey, Managing Director, HarbourVest Partners. “Our EMEA business continues to grow as we expand into new regions and client segments. TJ’s deep experience in the European market will help position our firm to maintain this growth path, while continuing to provide exceptional service to our clients across the region.” TJ has almost 30 years of experience in finance and has extensive leadership experience in the European market, most recently as Head of Private Markets Distribution in Europe for Morgan Stanley. Prior to that he held senior roles at Eaton Vance, where he was Head of Global Distribution, and Nuveen Investments, where he was Head of EMEA. TJ attended Nyenrode Business University in the Netherlands, where he earned his Bachelor a
Novotech Earns Great Place to Work® Certification in the United States19.9.2024 17:56:00 CEST | Press release
Novotech, a global full-service clinical Contract Research Organization (CRO), is proud to announce that it has been certified as a Great Place to Work® in the United States. This award reflects Novotech’s commitment to fostering a flexible, inclusive, and innovative work environment where employees feel supported and empowered to contribute to the future of medical research. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240919886365/en/ Novotech is a Great Place to Work Certified in the USA (Graphic: Business Wire) The certification is based on direct feedback from employees and highlights the supportive and collaborative culture Novotech has built in its U.S. offices. It underscores the company’s dedication to ensuring that its team members thrive, both professionally and personally. What makes Novotech a Great Place to Work? A welcoming and inclusive work culture where diversity is celebrated. Opportunities for career gr
Dubai Future Foundation Issues Special ‘Global 50’ Report on Youth Ahead of UN Summit19.9.2024 17:12:00 CEST | Press release
Compiled with contributions from international and UAE-based experts, the report focuses on innovative strategies to empower and support youth and future generations. The Dubai Future Foundation (DFF) has launched a special edition of its ‘Global 50’ report, exploring innovative solutions that empower youth and future generations. Released ahead of the 2024 United Nations' 'Summit of the Future', the ‘Global 50: Future Opportunities’ report complements the forthcoming UN 'Pact for the Future', ‘Declaration on Future Generations’ and ‘Global Digital Compact’, which focus on addressing challenges and opportunities of today and for years to come. This edition features insights from both international and UAE experts, spotlighting opportunities that drive innovation, address global challenges, and support sustainability. The strategies outlined aim to enhance public health, advance technology, stimulate economic growth, and promote environmental sustainability. By capitalizing on these opp
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom